PARP inhibition in combination with DNA alkylating agents has potent anti-tumour activity in Ewing’s sarcoma xenograft and orthotopic models [24, 29], and the use of PARP inhibitors (olaparib, niraparib and BMN-673) with temozolomide is currently being evaluated in clinical trials (NCT02044120, NCT01858168 and NCT02116777). The gene discussed is PARP1; the disease is Ewing sarcoma.